07:00 , Oct 29, 2007 |  BioCentury  |  Finance

Ebb & Flow

Biogen Idec (BIIB) was off last week on slowing sales of Avonex interferon beta-1a, eroding $3.50 to $76.72 for the week. On the company's conference call, President and CEO James Mullen said 3Q07 sales of...
00:39 , Oct 27, 2007 |  BC Extra  |  Financial News

NovaBay prices IPO

NovaBay (NBY; TSX:NBY) raised $20 million through the sale of 5 million shares at $4 in an IPO on the American Stock Exchange and the Toronto Stock Exchange. The deal price came in at the...
07:00 , Aug 13, 2007 |  BioCentury  |  Finance

Ebb & Flow

A pair of high-profile setbacks among two of Germany's late-stage biotech companies has left the country's biotech industry with only a handful of Phase III products. Thus, investors are starting to view the German landscape...
00:41 , Aug 11, 2007 |  BC Extra  |  Financial News

NovaBay amends IPO

NovaBay (Emeryville, Calif.) updated its IPO on the American Stock Exchange and the Toronto Stock Exchange and hopes to sell 5 million shares at $4-$6. The company also added Desjardins; Blackmont Capital; and Dawson James...
07:00 , Jul 3, 2006 |  BC Week In Review  |  Company News

Bioniche management update

Bioniche Life Sciences Inc. (TSX:BNC), Belleville, Ontario   Business: Cancer, Infectious, Inflammation   Hired: Cameron Groome as EVP of corporate and strategic development, formerly director of investment banking at Blackmont Capital Inc.  ...